| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123292 | European Journal of Cancer | 2010 | 10 Pages |
Abstract
The results from our study suggest that patients with advanced NSCLC who have severe co-existing disorders benefit from and tolerate platinum-doublet chemotherapy as well as other patients. They do, however, appear to have a higher risk of acquiring infections when neutropenic.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Bjørn H. Grønberg, Stein Sundstrøm, Stein Kaasa, Roy M. Bremnes, Ãystein Fløtten, Tore Amundsen, Harald H. Hjelde, Christian von Plessen, Marit Jordhøy,